Clinical Trial

Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 27, 2023 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Patients with newly diagnosed, pathologically confirmed NK/T-cell lymphoma of stage III-IV treated with XCOPL regimen. 3 weeks for a cycle, with a total of 6-8 cycles.
Trial Details
NCT Number NCT05833893
Lead Sponsor Chinese PLA General Hospital
Conditions nk/T-cell Lymphoma, Newly Diagnosed, Advanced Lymphoma
Enrollment 10 participants
Start Date 2023-05-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-04-27